Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 5911–5917 | Cite as

Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis

  • Bin Jin
  • Zhiwei Gong
  • Nongguo Yang
  • Zhaoquan Huang
  • Sien Zeng
  • Hui Chen
  • Sanyuan Hu
  • Guangdong Pan
Original Article

Abstract

Betaine homocysteine methyltransferase (BHMT) catalyzes the synthesis of methionine using betaine and homocysteine (Hcy), which is restricted to the liver and kidney. Impaired BHMT pathway has been associated with hepatocellular carcinogenesis in Bhmt−/− mice model, and decreased BHMT was observed in a small sample of human hepatocellular carcinoma (HCC) patients. However, the prognostic significance of BHMT in HCC has not been elucidated. This study aimed to examine the expression of BHMT in HCC and investigate the relationship between its expression and prognosis of HCC patients. BHMT expression was analyzed in 68 paired HCC samples (HCC tissues vs matched adjacent non-cancerous liver tissues), 115 paraffin-embedded HCC sections (primary cohort), and 65 paraffin-embedded HCC sections (validation cohort) using immunohistochemistry (IHC). The results of IHC analysis showed that BHMT was decreased in tumorous tissues in 85.2 % (58/68) of cases compared to the corresponding adjacent non-tumorous liver tissues. Further correlation analyses indicated that the decreased BHMT expression was closely correlated with serum α-fetoprotein (AFP) (p = 0.011), tumor size (p = 0.039), and vascular invasion (p = 0.017). Moreover, HCC patients with low BHMT expression had shorter overall survival (OS) and time to recurrence (TTR) than those with high BHMT expression in both primary cohort (p < 0.0001) and validation cohort (p < 0.05) assessed by the Kaplan–Meier method. In addition, multivariate analysis showed that BHMT was an independent prognostic factor for OS and TTR in the two cohorts (all p < 0.005). Collectively, our study demonstrated that BHMT could be served as a potential prognostic marker for HCC patients.

Keywords

BHMT Hepatocellular carcinoma Prognosis IHC 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (no. 81100323, no. 81160256), the Fundamental Research Funds of Shan Dong University (Qilu Hospital Research Project) (2014QLKY18), and the Project Fund of Techpool (UF201330).

Compliance with ethical guidelines

Conflict of interests

None

Supplementary information

Supplementary Figure 1, Supplementary Table 1–2.

Supplementary material

13277_2015_4443_MOESM1_ESM.doc (274 kb)
Supplementary Figure 1 Correlation of low BHMT expression with unfavorable OS and TTR in primary cohort and validation cohort, respectively. Probabilities of OS (A) and TTR (B) of 115 HCC patients (primary cohort) were analyzed using Kaplan-Meier survival analysis (log-rank test). Probabilities of OS (C) and TTR (D) of 65 HCC patients (validation cohort) were analyzed using Kaplan-Meier survival analysis (log-rank test). (DOC 274 kb)
13277_2015_4443_MOESM2_ESM.doc (92 kb)
Supplementary Table 1 Univariate and multivariate analysis of different prognostic parameters in primary cohort by Cox regression analysis (n=115). (DOC 92 kb)
13277_2015_4443_MOESM3_ESM.doc (88 kb)
Supplementary Table 2 Univariate and multivariate analysis of different prognostic parameters in validation cohort by Cox regression analysis (n=65). (DOC 88 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771–80.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Hiwatashi K, Ueno S, Sakoda M, et al. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. Ann Surg Oncol. 2009;16:3176–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Hu BS, Zhao G, Yu HF, et al. High expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Tumour Biol. 2013;34:271–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Lu HF, Yuan WP, Li M, et al. Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection. Tumour Biol. 2015;36:4937–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Jin H, Zhang Y, You H, et al. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep. 2015;5:10466.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Millian NS, Garrow TA. Human betaine-homocysteine methyltransferase is a zinc metalloenzyme. Arch Biochem Biophys. 1998;356:93–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Craig SAS. Betaine in human nutrition. Am J Clin Nutr. 2004;80:539–49.PubMedGoogle Scholar
  12. 12.
    Garcia-Perez A, Burg MB. Renal medullary organic osmolytes. Physiol Rev. 1991;71:1081–115.PubMedGoogle Scholar
  13. 13.
    Pajares MA, Perez-Sala D. Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? Cell Mol Life Sci. 2006;63:2792–803.CrossRefPubMedGoogle Scholar
  14. 14.
    Delgado-Reyes CV, Wallig MA, Garrow TA. Immunohistochemical detection of betaine-homocysteine S-methyltransferase in human, pig, and rat liver and kidney. Arch Biochem Biophys. 2001;393:184–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Sun J, Shannon M, Ando Y, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893:107–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Shinohara M, Ji C, Kaplowitz N. Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology. 2010;51:796–805.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang B, Denomme MM, White CR, et al. Both the folate cycle and betaine-homocysteine methyltransferase contribute methyl groups for DNA methylation in mouse blastocysts. FASEB J. 2015;29:1069–79.CrossRefPubMedGoogle Scholar
  18. 18.
    Pellanda H, Namour F, Fofou-Caillierez M, et al. A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma. Int J Biochem Cell Biol. 2012;44:385–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, et al. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res. 2011;10(8):3418–28.CrossRefPubMedGoogle Scholar
  21. 21.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2000;33:907–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Frau M, Simile MM, Tomasi ML, et al. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr). 2012;35:163–73.CrossRefGoogle Scholar
  25. 25.
    da Silva LM, Galbiatti AL, Ruiz MT, et al. MTHFD1 G1958A, BHMT G742A, TC2 C776G and TC2 A67G polymorphisms and head and neck squamous cell carcinoma risk. Mol Biol Rep. 2012;39:887–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Peng JP, Zhang J, Huang HW, et al. L-arginine-glycine amidinotransferase, betaine-homocysteine S-methyltransferase, and neuropolypeptide H3 are diminished in renal clear cell carcinoma of humans. Saudi Med J. 2011;32:467–73.PubMedGoogle Scholar
  27. 27.
    Mostowska A, Myka M, Lianeri M, et al. Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem. 2011;44:596–600.CrossRefPubMedGoogle Scholar
  28. 28.
    Teng YW, Mehedint MG, Garrow TA, et al. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011;286:36258–67.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Iida H, Honda M, Kawai HF, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut. 2005;54(6):843–51.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–31.CrossRefPubMedGoogle Scholar
  32. 32.
    Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol. 2010;10:146.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):1002–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52(6):880–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Bin Jin
    • 1
  • Zhiwei Gong
    • 1
    • 2
  • Nongguo Yang
    • 3
  • Zhaoquan Huang
    • 4
  • Sien Zeng
    • 4
  • Hui Chen
    • 5
  • Sanyuan Hu
    • 1
  • Guangdong Pan
    • 6
  1. 1.Department of General SurgeryQilu Hospital of Shandong UniversityJinanChina
  2. 2.Department of General SurgeryThe Qingzhou City People’s hospitalQingzhouChina
  3. 3.Department of General SurgeryThe people’s Hospital of LingChengDezhouChina
  4. 4.Department of PathologyAffiliated hospital of Guilin Medical UniversityGuilinChina
  5. 5.Laboratory of Liver Injury and Repair Molecular MedicineGuilin Medical UniversityGuilinChina
  6. 6.Department of Hepatobiliary SurgeryThe people’s hospital of LiuzhouLiuzhouChina

Personalised recommendations